- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
PDS Biotechnology Corp (PDSB)
"PDS Biotechnology Corp stock price live, this page displays NASDAQ PDSB stock exchange data. View the PDSB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the PDS Biotechnology Corp real time stock price chart below.
What Is the PDS Biotechnology Corp Stock Price Today?
The PDS Biotechnology Corp stock price today is 1.240.
What Is the Stock Symbol for PDS Biotechnology Corp?
The stock symbol for PDS Biotechnology Corp is ""PDSB.""
What Stock Exchange Does PDS Biotechnology Corp Trade On?
PDS Biotechnology Corp is listed and trades on the NASDAQ stock exchange.
Is PDS Biotechnology Corp a Good Stock to Buy?
Determining whether PDS Biotechnology Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PDSB quote. (ISIN: US70465T1079)"
What Is the PDS Biotechnology Corp Stock Price Today?
The PDS Biotechnology Corp stock price today is 1.240.
What Is the Stock Symbol for PDS Biotechnology Corp?
The stock symbol for PDS Biotechnology Corp is ""PDSB.""
What Stock Exchange Does PDS Biotechnology Corp Trade On?
PDS Biotechnology Corp is listed and trades on the NASDAQ stock exchange.
Is PDS Biotechnology Corp a Good Stock to Buy?
Determining whether PDS Biotechnology Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PDSB quote. (ISIN: US70465T1079)"
1.240
-0.010(-0.80%)
Closed·
After Hours
1.2400.000(0.00%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.210
1.290
52 wk Range
0.851
4.420
PDSB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2101.290
52 wk Range
0.8514.420
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PDSB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.500
Upside
+504.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
PDS Biotechnology Corp Company Profile
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company’s lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
PDS Biotechnology Corp Earnings Call Summary for Q4/2024
- Net loss narrowed to $37.6M in 2024 from $42.9M in 2023; R&D expenses reduced to $22.6M from $27.8M
- Initiated Phase III trial for Versimmune HPV; stock rose 4.84% in premarket trading on strategic advancements
- Raised $11M through direct offering in Feb 2025; cash balance of $41.7M as of Dec 31, 2024
- Exploring partnerships and non-dilutive funding; interim data readouts expected at 6 and 12 months
- Analyst consensus bullish with price targets $4.50-$21.00; potential for accelerated FDA approval discussions
Last Updated: 2025/03/27, 14:56
Read Full TranscriptCompare PDSB to Peers and Sector
Metrics to compare | PDSB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPDSBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −1.7x | −0.5x | |
PEG Ratio | −0.06 | 0.00 | 0.00 | |
Price/Book | 3.0x | 1.0x | 2.6x | |
Price / LTM Sales | - | 11.2x | 2.9x | |
Upside (Analyst Target) | 300.0% | 291.9% | 57.1% | |
Fair Value Upside | Unlock | 12.3% | 9.0% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.500
(+504.84% Upside)
Earnings
Latest Release
Mar 27, 2025
EPS / Forecast
-0.21 / -0.3083
Revenue / Forecast
-- / --
FAQ
What Is the PDS Biotech (PDSB) Stock Price Today?
The PDS Biotech stock price today is 1.24
What Stock Exchange Does PDS Biotech Trade On?
PDS Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for PDS Biotech?
The stock symbol for PDS Biotech is "PDSB."
What Is the PDS Biotech Market Cap?
As of today, PDS Biotech market cap is 55.84M.
What is PDS Biotech Earnings Per Share?
The PDS Biotech EPS is -1.03.
What Is the Next PDS Biotech Earnings Date?
PDS Biotech will release its next earnings report on 13 May 2025.
From a Technical Analysis Perspective, Is PDSB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.